For example, in patients with clinical diagnosis of bvFTD, tau-targeting therapeutics (e.g., tau aggregation inhibitors) may be administered in those with suspected FTLD-tau pathology. This evidence concerns the gene MAPT and behavioral variant of frontotemporal dementia.